Marta Turek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marta Turek has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Michalina Zagalska
Independent Public Clinical Hospital named Andrzej Mielęcki of the Silesian Medical University in Katowice, Francuska 20-24 Street, Katowice, Poland
13 shared publications - Adam Jan Ząbek
Katowice Oncology Center, Poland
11 shared publications - Emilia Gabriela Chrzanowska
Medical University of Silesia, Katowice, Poland
11 shared publications - Jakub Paweł Kuźniar
The Provincial Hospital in Bielsko Biała, Poland
11 shared publications - Julia Szlążek
Medical University of Silesia, 18 Medyków Street 40-752 Katowice
11 shared publications - Tomasz Tamborski
County Hospital in Zawiercie, Poland
11 shared publications
Latest Publications
- 28 November 2025
- Published by Index Copernicus in Medical Science Pulse
Atypical hemolytic- uremic syndrome (aHUS) – a rare disease, new hopes in treatment. Review
Atypical hemolytic uremic syndrome (aHUS) is a rare disease stemming from complement system dysregulation, manifesting as thrombotic microangiopathy (TMA). It is also described as a heritable, life-threatening disorder characterized by uncontrolled complement activation, leading to systemic TMA and damage to vital organs. aHUS is frequently considered a prototypical form of complement-mediated TMA (CM-TMA), resulting from the dysregulation and overactivation of the alternative complement pathway, culminating in excessive terminal complement activation. The classical clinical triad of aHUS encompasses thrombocytopenia, microangiopathic hemolytic anemia and acute kidney injury.This review paper aims to provide a comprehensive overview of atypical hemolytic uremic syndrome (aHUS). Specifically, this work intends to define aHUS, encompassing its pathomechanism, clinical presentation, and diagnostic criteria. Attention is also directed towards secondary aHUS, which can occur in association with various underlying conditions. Furthermore, this review covers current, available treatment modalities utilizing eculizumab and ravulizumab, providing a comparative analysis of these two agents and highlighting their significance as terminal complement pathway inhibitors. The fundamental mechanism underlying aHUS is the uncontrolled activation of the complement system, particularly its alternative pathway, leading to systemic TMA and life-threatening organ damage. The management of aHUS has been transformed with the introduction of terminal complement inhibitors, such as eculizumab and ravulizumab, which have demonstrated efficacy in improving hematological and renal parameters. Ravulizumab, a long-acting C5 inhibitor, allows for less frequent dosing compared to eculizumab. This paper underscores the importance of early recognition and the implementation of complement inhibitor therapy in aHUS and indicates the necessity for future comparative studies of eculizumab and ravulizumab to optimize treatment strategies.
- 28 November 2025
- Published by Index Copernicus in Medical Science Pulse
Atypical hemolytic- uremic syndrome (aHUS) – a rare disease, new hopes in treatment. Review
Atypical hemolytic uremic syndrome (aHUS) is a rare disease stemming from complement system dysregulation, manifesting as thrombotic microangiopathy (TMA). It is also described as a heritable, life-threatening disorder characterized by uncontrolled complement activation, leading to systemic TMA and damage to vital organs. aHUS is frequently considered a prototypical form of complement-mediated TMA (CM-TMA), resulting from the dysregulation and overactivation of the alternative complement pathway, culminating in excessive terminal complement activation. The classical clinical triad of aHUS encompasses thrombocytopenia, microangiopathic hemolytic anemia and acute kidney injury.This review paper aims to provide a comprehensive overview of atypical hemolytic uremic syndrome (aHUS). Specifically, this work intends to define aHUS, encompassing its pathomechanism, clinical presentation, and diagnostic criteria. Attention is also directed towards secondary aHUS, which can occur in association with various underlying conditions. Furthermore, this review covers current, available treatment modalities utilizing eculizumab and ravulizumab, providing a comparative analysis of these two agents and highlighting their significance as terminal complement pathway inhibitors. The fundamental mechanism underlying aHUS is the uncontrolled activation of the complement system, particularly its alternative pathway, leading to systemic TMA and life-threatening organ damage. The management of aHUS has been transformed with the introduction of terminal complement inhibitors, such as eculizumab and ravulizumab, which have demonstrated efficacy in improving hematological and renal parameters. Ravulizumab, a long-acting C5 inhibitor, allows for less frequent dosing compared to eculizumab. This paper underscores the importance of early recognition and the implementation of complement inhibitor therapy in aHUS and indicates the necessity for future comparative studies of eculizumab and ravulizumab to optimize treatment strategies.
- Open Access
- 29 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(47))
CHANGING THE TRAJECTORY OF GROWTH: THE APPLICATION OF VOSORITIDE IN CHILDREN WITH ACHONDROPLASIA. A CHANCE FOR IMPROVED QUALITY OF LIFE?
Achondroplasia (ACH) is the most common skeletal dysplasia and the leading genetic cause of dwarfism. It is characterized by disproportionate short stature and lifelong medical complications, with an estimated incidence of 1 in 25,000–30,000 live births. The condition results from a mutation in the fibroblast growth factor receptor 3 (FGFR3) gene, causing receptor overactivation and impaired bone growth at the growth plates. This review provides an overview of achondroplasia, including its pathophysiology, clinical features, diagnostic methods, and novel therapeutic options, with emphasis on vosoritide. Historically, management has focused on symptomatic treatment and surgical interventions to address complications such as foramen magnum stenosis, hydrocephalus, and postural deformities. Vosoritide (Voxzogo) marks a breakthrough as the first disease-modifying therapy targeting the underlying pathophysiology. It is a C-type natriuretic peptide (CNP) analog that inhibits the overactive MAPK pathway, thereby promoting chondrocyte proliferation and differentiation in growth plates and enabling endochondral bone growth. Phase 3 clinical trials demonstrated that vosoritide significantly increases annual growth velocity (by approximately 1.57 cm) and improves body proportions, with a favorable safety profile. Reported adverse effects were generally mild, including transient hypotension and injection site reactions. Despite these advances, vosoritide therapy does not eliminate the need for coordinated multidisciplinary care and psychological support. Patients require ongoing monitoring and management of associated complications, including neurological, orthopedic, respiratory, and developmental issues. In summary, achondroplasia remains the most frequent genetic form of dwarfism, traditionally managed through supportive care and surgery. The introduction of vosoritide represents a paradigm shift, offering the first targeted therapy that directly modifies disease progression and opens new perspectives for improving patients’ quality of life.
- 29 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(47))
Open AccessCHANGING THE TRAJECTORY OF GROWTH: THE APPLICATION OF VOSORITIDE IN CHILDREN WITH ACHONDROPLASIA. A CHANCE FOR IMPROVED QUALITY OF LIFE?
Achondroplasia (ACH) is the most common skeletal dysplasia and the leading genetic cause of dwarfism. It is characterized by disproportionate short stature and lifelong medical complications, with an estimated incidence of 1 in 25,000–30,000 live births. The condition results from a mutation in the fibroblast growth factor receptor 3 (FGFR3) gene, causing receptor overactivation and impaired bone growth at the growth plates. This review provides an overview of achondroplasia, including its pathophysiology, clinical features, diagnostic methods, and novel therapeutic options, with emphasis on vosoritide. Historically, management has focused on symptomatic treatment and surgical interventions to address complications such as foramen magnum stenosis, hydrocephalus, and postural deformities. Vosoritide (Voxzogo) marks a breakthrough as the first disease-modifying therapy targeting the underlying pathophysiology. It is a C-type natriuretic peptide (CNP) analog that inhibits the overactive MAPK pathway, thereby promoting chondrocyte proliferation and differentiation in growth plates and enabling endochondral bone growth. Phase 3 clinical trials demonstrated that vosoritide significantly increases annual growth velocity (by approximately 1.57 cm) and improves body proportions, with a favorable safety profile. Reported adverse effects were generally mild, including transient hypotension and injection site reactions. Despite these advances, vosoritide therapy does not eliminate the need for coordinated multidisciplinary care and psychological support. Patients require ongoing monitoring and management of associated complications, including neurological, orthopedic, respiratory, and developmental issues. In summary, achondroplasia remains the most frequent genetic form of dwarfism, traditionally managed through supportive care and surgery. The introduction of vosoritide represents a paradigm shift, offering the first targeted therapy that directly modifies disease progression and opens new perspectives for improving patients’ quality of life.
- 24 September 2025
- Published by Index Copernicus in Medical Science Pulse
Air trapping - exercise-induced asthma (EIA): pathomechanism, diagnosis and novel prevention strategies
Background: Exercise-induced asthma (EIA), also known as exercise-induced bronchoconstriction (EIB), is characterized by transient airway narrowing triggered by physical exertion, leading to symptoms such as cough, wheezing, shortness of breath, and chest tightness. The pathophysiology of EIA involves osmotic and thermal mechanisms, resulting in the release of inflammatory mediators that induce bronchospasm.Aim of the study: This systematic review aims to elucidate the pathomechanisms, diagnostic approaches, and treatment modalities for EIA.Material and methods: The review follows PRISMA guidelines and includes 31 studies from PubMed and ClinicalTrials.gov, focusing on adults reporting EIA symptoms. Diagnostic methods primarily include spirometry pre- and post-exercise, with a ≥10% decrease in FEV1 indicating EIA. Provocation tests, such as eucapnic voluntary hyperventilation (EVH), and novel methods like diaphragm electromyography (EMGdi), are also explored.Results: Management strategies encompass pharmacological treatments, including short-acting beta-2 agonists (SABAs), inhaled corticosteroids (ICS), and leukotriene receptor antagonists (LTRAs), alongside non-pharmacological approaches like warm-up exercises and breathing retraining, which have been reviewed as parts of phase 3 and phase 4 clinical trials. The consistent use of standardised exercise challenge tests and FEV1 measurements, along with robust study designs, strengthens the evidence for prevention method efficacy.Conclusions: The review highlights the need for standardized diagnostic criteria and personalised treatment plans to improve patient outcomes and quality of life.
- 24 September 2025
- Published by Index Copernicus in Medical Science Pulse
Air trapping - exercise-induced asthma (EIA): pathomechanism, diagnosis and novel prevention strategies
Background: Exercise-induced asthma (EIA), also known as exercise-induced bronchoconstriction (EIB), is characterized by transient airway narrowing triggered by physical exertion, leading to symptoms such as cough, wheezing, shortness of breath, and chest tightness. The pathophysiology of EIA involves osmotic and thermal mechanisms, resulting in the release of inflammatory mediators that induce bronchospasm.Aim of the study: This systematic review aims to elucidate the pathomechanisms, diagnostic approaches, and treatment modalities for EIA.Material and methods: The review follows PRISMA guidelines and includes 31 studies from PubMed and ClinicalTrials.gov, focusing on adults reporting EIA symptoms. Diagnostic methods primarily include spirometry pre- and post-exercise, with a ≥10% decrease in FEV1 indicating EIA. Provocation tests, such as eucapnic voluntary hyperventilation (EVH), and novel methods like diaphragm electromyography (EMGdi), are also explored.Results: Management strategies encompass pharmacological treatments, including short-acting beta-2 agonists (SABAs), inhaled corticosteroids (ICS), and leukotriene receptor antagonists (LTRAs), alongside non-pharmacological approaches like warm-up exercises and breathing retraining, which have been reviewed as parts of phase 3 and phase 4 clinical trials. The consistent use of standardised exercise challenge tests and FEV1 measurements, along with robust study designs, strengthens the evidence for prevention method efficacy.Conclusions: The review highlights the need for standardized diagnostic criteria and personalised treatment plans to improve patient outcomes and quality of life.
- Open Access
- 23 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(47))
THE IMPACT OF REGULAR PHYSICAL ACTIVITY ON REDUCING EXACERBATION FREQUENCY, ENHANCING DISEASE CONTROL, AND IMPROVING QUALITY OF LIFE IN PATIENTS WITH BRONCHIAL ASTHMA
Introduction: Bronchial asthma is a chronic inflammatory airway disease with variable obstruction and hyperresponsiveness. Symptoms such as wheezing, dyspnea, chest tightness, and coughing fluctuate over time. Globally, asthma affects over 235 million people and represents a major health and economic burden. While physical exertion was once discouraged due to exercise-induced bronchoconstriction (EIB), current guidelines, including GINA, recommend regular physical activity as part of management. Objective: To evaluate whether physical activity benefits asthma patients of varying severity by improving control, reducing exacerbations, and enhancing quality of life. Methods: A narrative literature review was performed using PubMed. Inclusion criteria: English-language full texts from 2013–2025, limited to reviews and RCTs. Eighteen relevant articles were analyzed. Results: Exercise improves asthma control (e.g., 23% ACQ improvement in REACT) and quality of life (AQLQ). It reduces exacerbations and reliever use (53% vs. 20% exacerbation-free in one study). Aerobic training enhances FEV1 and FVC, while Inspiratory Muscle Training increases PImax. No consistent effect on airway inflammation was observed. Recommended modalities include aerobic, resistance, and flexibility training individualized via the FITT principle. Aquatic exercise may lower EIB risk due to humid air. EIB is managed by warm-up routines, pre-exercise SABAs, ICS for control, and optional ICS-LABA or LTRA. Benefits are pronounced in obese and moderate/severe asthma, especially with weight loss. Monitoring air quality and symptoms during activity is essential. Conclusion: Regular physical activity is safe, cost-effective, and improves asthma outcomes when tailored and combined with appropriate EIB management.
- 23 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(47))
Open AccessTHE IMPACT OF REGULAR PHYSICAL ACTIVITY ON REDUCING EXACERBATION FREQUENCY, ENHANCING DISEASE CONTROL, AND IMPROVING QUALITY OF LIFE IN PATIENTS WITH BRONCHIAL ASTHMA
Introduction: Bronchial asthma is a chronic inflammatory airway disease with variable obstruction and hyperresponsiveness. Symptoms such as wheezing, dyspnea, chest tightness, and coughing fluctuate over time. Globally, asthma affects over 235 million people and represents a major health and economic burden. While physical exertion was once discouraged due to exercise-induced bronchoconstriction (EIB), current guidelines, including GINA, recommend regular physical activity as part of management. Objective: To evaluate whether physical activity benefits asthma patients of varying severity by improving control, reducing exacerbations, and enhancing quality of life. Methods: A narrative literature review was performed using PubMed. Inclusion criteria: English-language full texts from 2013–2025, limited to reviews and RCTs. Eighteen relevant articles were analyzed. Results: Exercise improves asthma control (e.g., 23% ACQ improvement in REACT) and quality of life (AQLQ). It reduces exacerbations and reliever use (53% vs. 20% exacerbation-free in one study). Aerobic training enhances FEV1 and FVC, while Inspiratory Muscle Training increases PImax. No consistent effect on airway inflammation was observed. Recommended modalities include aerobic, resistance, and flexibility training individualized via the FITT principle. Aquatic exercise may lower EIB risk due to humid air. EIB is managed by warm-up routines, pre-exercise SABAs, ICS for control, and optional ICS-LABA or LTRA. Benefits are pronounced in obese and moderate/severe asthma, especially with weight loss. Monitoring air quality and symptoms during activity is essential. Conclusion: Regular physical activity is safe, cost-effective, and improves asthma outcomes when tailored and combined with appropriate EIB management.
- Open Access
- 23 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(47))
THE MULTIDIMENSIONAL IMPACT OF HIGH-INTENSITY INTERVAL TRAINING (HIIT) ON GLYCEMIC CONTROL, CARDIORESPIRATORY FITNESS, BODY COMPOSITION, AND METABOLIC AND INFLAMMATORY MARKERS IN PATIENTS WITH TYPE 2 DIABETES: A REVIEW OF EVIDENCE AND CLINICAL IMPLICATION
Introduction: Type 2 Diabetes Mellitus (T2DM) is a major global health burden, marked by chronic hyperglycemia and complications. Physical activity is central to management, with High-Intensity Interval Training (HIIT) emerging as a time-efficient, evidence-based approach. This review examines HIIT’s impact on glycemic control, cardiorespiratory fitness, body composition, and inflammation, also addressing safety and feasibility. Methods: A narrative review was conducted via PubMed using terms such as”Type 2 Diabetes, "“glycemia, "“HbA1c, "“physical activity, " and”HIIT." From forty articles screened, nineteen met inclusion criteria. Results and Discussion: HIIT effectively improves T2DM outcomes. It lowers HbA1c, fasting and postprandial glucose, and enhances insulin sensitivity and beta-cell function. Compared to moderate-intensity continuous training (MICT), HIIT often yields superior VO₂max improvements. It also reduces BMI, total and visceral fat, and improves lipid profiles. HIIT is associated with lower inflammatory markers. Implementation is feasible and safe, even for older adults, with high adherence and minimal adverse events. Conclusion: HIIT is a potent non-pharmacological tool in T2DM management, offering benefits across metabolic and cardiovascular domains. Its ability to improve glycemic control, fitness, body composition, and inflammation underscores its clinical relevance. Current evidence supports integrating HIIT into standard care for T2DM patients.
- 23 September 2025
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(47))
Open AccessTHE MULTIDIMENSIONAL IMPACT OF HIGH-INTENSITY INTERVAL TRAINING (HIIT) ON GLYCEMIC CONTROL, CARDIORESPIRATORY FITNESS, BODY COMPOSITION, AND METABOLIC AND INFLAMMATORY MARKERS IN PATIENTS WITH TYPE 2 DIABETES: A REVIEW OF EVIDENCE AND CLINICAL IMPLICATION
Introduction: Type 2 Diabetes Mellitus (T2DM) is a major global health burden, marked by chronic hyperglycemia and complications. Physical activity is central to management, with High-Intensity Interval Training (HIIT) emerging as a time-efficient, evidence-based approach. This review examines HIIT’s impact on glycemic control, cardiorespiratory fitness, body composition, and inflammation, also addressing safety and feasibility. Methods: A narrative review was conducted via PubMed using terms such as”Type 2 Diabetes, "“glycemia, "“HbA1c, "“physical activity, " and”HIIT." From forty articles screened, nineteen met inclusion criteria. Results and Discussion: HIIT effectively improves T2DM outcomes. It lowers HbA1c, fasting and postprandial glucose, and enhances insulin sensitivity and beta-cell function. Compared to moderate-intensity continuous training (MICT), HIIT often yields superior VO₂max improvements. It also reduces BMI, total and visceral fat, and improves lipid profiles. HIIT is associated with lower inflammatory markers. Implementation is feasible and safe, even for older adults, with high adherence and minimal adverse events. Conclusion: HIIT is a potent non-pharmacological tool in T2DM management, offering benefits across metabolic and cardiovascular domains. Its ability to improve glycemic control, fitness, body composition, and inflammation underscores its clinical relevance. Current evidence supports integrating HIIT into standard care for T2DM patients.
- Open Access
- 1 June 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 82, 60285
The Impact of Physical Activity on the Course of Inflammatory Bowel Diseases
Inflammatory bowel diseases (IBD) including Crohn's disease (CD) and ulcerative colitis (UC), are chronic, immune-mediated conditions with increasing global prevalence. While the etiology of IBD is multifactorial—encompassing genetic, environmental, microbial, and immunological components—emerging evidence highlights the role of lifestyle factors, such as physical activity (PA), in modulating disease mechanisms and outcomes. This review explores the multifaceted impact of PA on IBD, focusing on gut microbiota composition, intestinal barrier integrity, and immune function. Moderate, regular exercise has been shown to beneficially influence gut microbial diversity, promote the production of anti-inflammatory metabolites, and support mucosal barrier function. Additionally, PA modulates systemic and intestinal immune responses, potentially reducing pro-inflammatory cytokine activity. In CD, visceral adiposity and adipokine dysregulation further complicate disease progression, suggesting a specific relevance of PA in this patient group. While observational and interventional studies indicate that PA may reduce anxiety and improve quality of life in IBD patients, the evidence regarding its effects on somatic symptoms and disease course remains inconclusive. Future randomized controlled trials are essential to establish standardized exercise protocols and clarify the therapeutic potential of PA in IBD management. Nonetheless, current data support PA as a safe, promising adjunct to conventional therapies, with potential benefits for both physical and psychological health in IBD patients.
- 1 June 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 82, 60285
Open AccessThe Impact of Physical Activity on the Course of Inflammatory Bowel Diseases
Inflammatory bowel diseases (IBD) including Crohn's disease (CD) and ulcerative colitis (UC), are chronic, immune-mediated conditions with increasing global prevalence. While the etiology of IBD is multifactorial—encompassing genetic, environmental, microbial, and immunological components—emerging evidence highlights the role of lifestyle factors, such as physical activity (PA), in modulating disease mechanisms and outcomes. This review explores the multifaceted impact of PA on IBD, focusing on gut microbiota composition, intestinal barrier integrity, and immune function. Moderate, regular exercise has been shown to beneficially influence gut microbial diversity, promote the production of anti-inflammatory metabolites, and support mucosal barrier function. Additionally, PA modulates systemic and intestinal immune responses, potentially reducing pro-inflammatory cytokine activity. In CD, visceral adiposity and adipokine dysregulation further complicate disease progression, suggesting a specific relevance of PA in this patient group. While observational and interventional studies indicate that PA may reduce anxiety and improve quality of life in IBD patients, the evidence regarding its effects on somatic symptoms and disease course remains inconclusive. Future randomized controlled trials are essential to establish standardized exercise protocols and clarify the therapeutic potential of PA in IBD management. Nonetheless, current data support PA as a safe, promising adjunct to conventional therapies, with potential benefits for both physical and psychological health in IBD patients.
- Open Access
- 19 May 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 80, 60160
Nanotechnology in the Treatment of Glioblastoma Multiforme: Enhancing Radiotherapy and Chemotherapy with Nanoparticles
Introduction: Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor, associated with poor prognosis despite standard treatment modalities including surgery, radiotherapy, and chemotherapy. The limited efficacy of these therapies is due, in part, to the difficulty of complete tumor resection, the blood-brain barrier (BBB) hindering drug penetration, and the tumor’s resistance mechanisms to chemotherapy and radiotherapy. Nanoparticles (NPs) offer promising solutions for targeted drug delivery, potentially improving therapeutic outcomes. This review summarizes recent advances in nanoparticle-based therapies for GBM. Methods: A literature review was conducted by analyzing 38 scientific articles using PubMed and Google Scholar databases. Studies published within the last five years focusing on the application of nanoparticles in GBM treatment were included. Various types of nanoparticles, their mechanisms of action, and the potential benefits and limitations of their clinical use were discussed. Results: The literature indicates that nanoparticles enhance drug permeability across the BBB, improve tumor penetration, and increase treatment efficacy. Their use in GBM therapy enables more precise drug delivery, reduces systemic toxicity, and minimizes damage to healthy tissues. Furthermore, nanoparticles play a significant role in combination therapies, potentially leading to a synergistic therapeutic effect. Conclusions: Nanoparticles represent a novel and promising strategy for the treatment of GBM, offering targeted drug delivery and improved therapeutic outcomes. However, further research is needed to optimize nanoparticle formulations and to evaluate their long-term safety and efficacy in clinical settings.
- 19 May 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 80, 60160
Open AccessNanotechnology in the Treatment of Glioblastoma Multiforme: Enhancing Radiotherapy and Chemotherapy with Nanoparticles
Introduction: Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor, associated with poor prognosis despite standard treatment modalities including surgery, radiotherapy, and chemotherapy. The limited efficacy of these therapies is due, in part, to the difficulty of complete tumor resection, the blood-brain barrier (BBB) hindering drug penetration, and the tumor’s resistance mechanisms to chemotherapy and radiotherapy. Nanoparticles (NPs) offer promising solutions for targeted drug delivery, potentially improving therapeutic outcomes. This review summarizes recent advances in nanoparticle-based therapies for GBM. Methods: A literature review was conducted by analyzing 38 scientific articles using PubMed and Google Scholar databases. Studies published within the last five years focusing on the application of nanoparticles in GBM treatment were included. Various types of nanoparticles, their mechanisms of action, and the potential benefits and limitations of their clinical use were discussed. Results: The literature indicates that nanoparticles enhance drug permeability across the BBB, improve tumor penetration, and increase treatment efficacy. Their use in GBM therapy enables more precise drug delivery, reduces systemic toxicity, and minimizes damage to healthy tissues. Furthermore, nanoparticles play a significant role in combination therapies, potentially leading to a synergistic therapeutic effect. Conclusions: Nanoparticles represent a novel and promising strategy for the treatment of GBM, offering targeted drug delivery and improved therapeutic outcomes. However, further research is needed to optimize nanoparticle formulations and to evaluate their long-term safety and efficacy in clinical settings.
- Open Access
- 19 May 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 80, 60159
Innovative Approaches in the Treatment of Pancreatic Cancer: The Role of CAR T-Cell Therapy
IntroductionPancreatic ductal adenocarcinoma (PDAC) is one of the most lethal gastrointestinal cancers, marked by late diagnosis, rapid progression, and resistance to treatment, resulting in a five-year survival rate below 10%. Chimeric antigen receptor T-cell (CAR T-cell) therapy has shown success in hematologic malignancies, sparking interest in its potential for solid tumors like PDAC. This paper reviews current knowledge on CAR T-cell therapy in PDAC, focusing on challenges, future prospects, and available studies. MethodologyThis literature review is based on a search of PubMed and Google Scholar for publications from the last 10 years. Fifty sources, including original studies, reviews, and clinical reports, were analyzed with focus on mechanisms of action, preclinical/clinical outcomes, safety, and toxicity. ResultsStudies show that CAR T-cell therapy can stabilize PDAC and even induce remission when targeting tumor-specific antigens. However, major obstacles remain: poor tumor penetration, toxicity (e.g., cytokine release syndrome), and "on-target, off-tumor" effects. Clinical trials report modest CAR T-cell expansion and persistence, suggesting the need for improved design and strategies. ConclusionsWhile CAR T-cell therapy for PDAC is promising, its effectiveness is hindered by the tumor microenvironment and side effects. Future directions include better antigen targeting, modified CAR constructs, combination therapies, and personalized or allogeneic CAR T-cell approaches to enhance outcomes in this difficult-to-treat cancer.
- 19 May 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 80, 60159
Open AccessInnovative Approaches in the Treatment of Pancreatic Cancer: The Role of CAR T-Cell Therapy
IntroductionPancreatic ductal adenocarcinoma (PDAC) is one of the most lethal gastrointestinal cancers, marked by late diagnosis, rapid progression, and resistance to treatment, resulting in a five-year survival rate below 10%. Chimeric antigen receptor T-cell (CAR T-cell) therapy has shown success in hematologic malignancies, sparking interest in its potential for solid tumors like PDAC. This paper reviews current knowledge on CAR T-cell therapy in PDAC, focusing on challenges, future prospects, and available studies. MethodologyThis literature review is based on a search of PubMed and Google Scholar for publications from the last 10 years. Fifty sources, including original studies, reviews, and clinical reports, were analyzed with focus on mechanisms of action, preclinical/clinical outcomes, safety, and toxicity. ResultsStudies show that CAR T-cell therapy can stabilize PDAC and even induce remission when targeting tumor-specific antigens. However, major obstacles remain: poor tumor penetration, toxicity (e.g., cytokine release syndrome), and "on-target, off-tumor" effects. Clinical trials report modest CAR T-cell expansion and persistence, suggesting the need for improved design and strategies. ConclusionsWhile CAR T-cell therapy for PDAC is promising, its effectiveness is hindered by the tumor microenvironment and side effects. Future directions include better antigen targeting, modified CAR constructs, combination therapies, and personalized or allogeneic CAR T-cell approaches to enhance outcomes in this difficult-to-treat cancer.
- Open Access
- 10 May 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 80, 60052
The Evolution of Methotrexate Applications: A Multidimensional Approach to Treating Various Disorders – A Literature Review
IntroductionMethotrexate (MTX) is a key cytostatic and immunosuppressive drug widely used in oncology and autoimmune disease treatment. It acts as a folic acid antagonist, inhibiting DNA synthesis and cell division. This review explores new applications of MTX beyond its traditional role. MTX shows potential in treating neuromyelitis optica spectrum disorders (NMOSD) as an alternative when other immunosuppressants are ineffective. In ophthalmic diseases like non-infectious uveitis and scleritis, it reduces inflammation and corticosteroid dependence. MTX is also used for unruptured ectopic pregnancy as a non-surgical option in select cases, with meta-analyses confirming its effectiveness, though resolution times may vary. Additionally, emerging evidence suggests MTX may help prevent cardiovascular diseases in patients with inflammatory conditions by improving atherosclerosis biomarkers. ObjectiveThis review aims to provide an overview of MTX’s expanding applications, pharmacological properties, and the importance of therapy monitoring. Current State of KnowledgeMTX is well-established in both low doses for autoimmune diseases like rheumatoid arthritis and high doses for chemotherapy. While effective, it has significant toxicity risks, particularly at high doses, necessitating therapeutic drug monitoring (TDM) to minimize adverse effects like nephrotoxicity and mucositis. MethodsThis review synthesizes data from review articles, original studies, meta-analyses, and clinical guidelines, covering MTX’s mechanisms, pharmacokinetics, clinical applications, toxicity management, and TDM role. ConclusionsMTX remains a cornerstone in disease treatment due to its broad pharmacological spectrum. Effective therapy requires proper dosing, toxicity management, and monitoring strategies. Ongoing research seeks to optimize MTX use while minimizing risks.
- 10 May 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 80, 60052
Open AccessThe Evolution of Methotrexate Applications: A Multidimensional Approach to Treating Various Disorders – A Literature Review
IntroductionMethotrexate (MTX) is a key cytostatic and immunosuppressive drug widely used in oncology and autoimmune disease treatment. It acts as a folic acid antagonist, inhibiting DNA synthesis and cell division. This review explores new applications of MTX beyond its traditional role. MTX shows potential in treating neuromyelitis optica spectrum disorders (NMOSD) as an alternative when other immunosuppressants are ineffective. In ophthalmic diseases like non-infectious uveitis and scleritis, it reduces inflammation and corticosteroid dependence. MTX is also used for unruptured ectopic pregnancy as a non-surgical option in select cases, with meta-analyses confirming its effectiveness, though resolution times may vary. Additionally, emerging evidence suggests MTX may help prevent cardiovascular diseases in patients with inflammatory conditions by improving atherosclerosis biomarkers. ObjectiveThis review aims to provide an overview of MTX’s expanding applications, pharmacological properties, and the importance of therapy monitoring. Current State of KnowledgeMTX is well-established in both low doses for autoimmune diseases like rheumatoid arthritis and high doses for chemotherapy. While effective, it has significant toxicity risks, particularly at high doses, necessitating therapeutic drug monitoring (TDM) to minimize adverse effects like nephrotoxicity and mucositis. MethodsThis review synthesizes data from review articles, original studies, meta-analyses, and clinical guidelines, covering MTX’s mechanisms, pharmacokinetics, clinical applications, toxicity management, and TDM role. ConclusionsMTX remains a cornerstone in disease treatment due to its broad pharmacological spectrum. Effective therapy requires proper dosing, toxicity management, and monitoring strategies. Ongoing research seeks to optimize MTX use while minimizing risks.
- Open Access
- 7 May 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 81, 59794
Thalidomide - a chance for use in modern disease treatment?
Thalidomide, despite its controversial history associated with teratogenic effects is currently used in the treatment of various conditions including oncological, immunological and dermatological diseases. The drug exhibits anti-inflammatory, immunomodulatory and anti-angiogenic effects, making it potentially effective in the treatment of various diseases. The mechanism of action is based on modulating the CRL4CRBN E3 ubiquitin ligase complex by binding to cereblon (CRBN), which leads to a change in the substrates recognized by this complex and the degradation of specific proteins. Thalidomide is used in the treatment of multiple myeloma, especially in cases resistant to other treatment methods. In addition, it can support the treatment of glioblastoma multiforme due to its anti-angiogenic and immunomodulatory effects. It is also used in the treatment of Crohn's disease, systemic lupus erythematosus, and idiopathic pulmonary fibrosis (IPF). In Crohn's disease it works by blocking TNF-α and modulating the immune response. In cutaneous lupus erythematosus it reduces inflammation, modulates the immune response and inhibits angiogenesis. In IPF, it inhibits the production of pro-inflammatory cytokines and reduces oxidative stress. The use of thalidomide is associated with a risk of teratogenicity, which requires strict control and the use of effective methods of contraception. In addition thalidomide can cause side effects, mainly hematological and gastrointestinal disorders. Due to the side effect profile, the use of thalidomide requires caution and close monitoring of the patient by a physician.
- 7 May 2025
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 81, 59794
Open AccessThalidomide - a chance for use in modern disease treatment?
Thalidomide, despite its controversial history associated with teratogenic effects is currently used in the treatment of various conditions including oncological, immunological and dermatological diseases. The drug exhibits anti-inflammatory, immunomodulatory and anti-angiogenic effects, making it potentially effective in the treatment of various diseases. The mechanism of action is based on modulating the CRL4CRBN E3 ubiquitin ligase complex by binding to cereblon (CRBN), which leads to a change in the substrates recognized by this complex and the degradation of specific proteins. Thalidomide is used in the treatment of multiple myeloma, especially in cases resistant to other treatment methods. In addition, it can support the treatment of glioblastoma multiforme due to its anti-angiogenic and immunomodulatory effects. It is also used in the treatment of Crohn's disease, systemic lupus erythematosus, and idiopathic pulmonary fibrosis (IPF). In Crohn's disease it works by blocking TNF-α and modulating the immune response. In cutaneous lupus erythematosus it reduces inflammation, modulates the immune response and inhibits angiogenesis. In IPF, it inhibits the production of pro-inflammatory cytokines and reduces oxidative stress. The use of thalidomide is associated with a risk of teratogenicity, which requires strict control and the use of effective methods of contraception. In addition thalidomide can cause side effects, mainly hematological and gastrointestinal disorders. Due to the side effect profile, the use of thalidomide requires caution and close monitoring of the patient by a physician.